BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $24.78 billion. The enterprise value is $9.76 billion.
| Market Cap | 24.78B |
| Enterprise Value | 9.76B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 251.20 million shares outstanding. The number of shares has increased by 3.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 251.20M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 16.35% |
| Owned by Institutions (%) | 20.17% |
| Float | 108.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.19 |
| Forward PS | 13.38 |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | 45.43 |
| P/OCF Ratio | 31.36 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 17.89 |
Financial Position
The company has a current ratio of 7.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.85 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.66 |
| Interest Coverage | -127.06 |
Financial Efficiency
Return on equity (ROE) is -9.30% and return on invested capital (ROIC) is -36.69%.
| Return on Equity (ROE) | -9.30% |
| Return on Assets (ROA) | -5.41% |
| Return on Invested Capital (ROIC) | -36.69% |
| Return on Capital Employed (ROCE) | -9.88% |
| Weighted Average Cost of Capital (WACC) | 11.25% |
| Revenue Per Employee | $387,797 |
| Profits Per Employee | -$246,785 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.74 |
Taxes
In the past 12 months, BioNTech SE has paid $65.01 million in taxes.
| Income Tax | 65.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.27% in the last 52 weeks. The beta is 1.29, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -12.27% |
| 50-Day Moving Average | 96.66 |
| 200-Day Moving Average | 97.65 |
| Relative Strength Index (RSI) | 46.12 |
| Average Volume (20 Days) | 1,717,287 |
Short Selling Information
The latest short interest is 2.51 million, so 3.76% of the outstanding shares have been sold short.
| Short Interest | 2.51M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 3.76% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.72 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.03 billion and -$1.93 billion in losses. Loss per share was -$7.77.
| Revenue | 3.03B |
| Gross Profit | 2.32B |
| Operating Income | -2.08B |
| Pretax Income | -1.86B |
| Net Income | -1.93B |
| EBITDA | -1.58B |
| EBIT | -2.08B |
| Loss Per Share | -$7.77 |
Balance Sheet
The company has $15.38 billion in cash and $361.13 million in debt, with a net cash position of $15.02 billion or $59.80 per share.
| Cash & Cash Equivalents | 15.38B |
| Total Debt | 361.13M |
| Net Cash | 15.02B |
| Net Cash Per Share | $59.80 |
| Equity (Book Value) | 20.29B |
| Book Value Per Share | 80.76 |
| Working Capital | 15.25B |
Cash Flow
In the last 12 months, operating cash flow was $790.34 million and capital expenditures -$244.77 million, giving a free cash flow of $545.58 million.
| Operating Cash Flow | 790.34M |
| Capital Expenditures | -244.77M |
| Depreciation & Amortization | 507.21M |
| Net Borrowing | 27.09M |
| Free Cash Flow | 545.58M |
| FCF Per Share | $2.17 |
Margins
Gross margin is 76.62%, with operating and profit margins of -68.57% and -63.64%.
| Gross Margin | 76.62% |
| Operating Margin | -68.57% |
| Pretax Margin | -61.49% |
| Profit Margin | -63.64% |
| EBITDA Margin | -52.11% |
| EBIT Margin | -68.57% |
| FCF Margin | 17.71% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -7.77% |
| FCF Yield | 2.20% |
Analyst Forecast
The average price target for BioNTech SE is $120.24, which is 21.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $120.24 |
| Price Target Difference | 21.87% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | -7.16% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.71 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.71 |
| Piotroski F-Score | 2 |